米索前列醇用于宫腔镜手术前促宫颈软化作用机制的探讨被引量：12

导出

摘要目的:研究宫腔镜手术前阴道置米索前列醇促宫颈软化作用的机制。方法:采用免疫组织化学方法检测实验A组(39例宫腔镜术前2 h阴道置米索前列醇200μg)和实验B组(29例宫腔镜术前2 h阴道置米索前列醇400μg)以及对照组(30例不用任何药物)宫颈组织中基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的表达,并比较各组宫颈组织中MMP-2和MMP-9表达的差异。同时对于实验组用药前后进行宫颈非用力最大扩张度的测定,分析用药前后宫颈非用力最大扩张度的差异。结果:1实验A组和实验B组用药前后宫颈非用力最大扩张度明显增加,两组用药前后比较差异均有统计学意义(P<0.001);2实验A组宫颈组织中MMP-9的表达与对照组比较,差异有统计学意义(P<0.01);实验B组MMP-9的表达与对照组比较,差异无统计学意义(P>0.05);实验A组MMP-9的表达与实验B组比较,差异有统计学意义(P<0.05);3实验A组MMP-2的表达与对照组比较,差异有统计学意义(P<0.05);实验B组MMP-2的表达与对照组比较,差异无统计学意义(P>0.05);实验A组MMP-2的表达与实验B组比较,差异无统计学意义(P>0.05);结论:阴道置米索前列醇后能够促进宫腔镜手术患者的宫颈软化,并且能够上调MMP-2、MMP-9的表达,提示宫腔镜手术前2 h阴道置米索前列醇可以使宫颈软化,利于手术操作。

作者原玮曹树军高丽萍杨道华秋承敏

机构地区上海交通大学附属第一人民医院松江分院妇产科上海长征医院病理科上海交通大学附属第一人民医院松江分院病理科

出处《中国妇幼保健》 CAS 2015年第7期1115-1117,共3页 Maternal and Child Health Care of China

关键词米索前列醇宫颈软化基质金属蛋白酶宫腔镜电切术

分类号 R713 [医药卫生—妇产科学]

引文网络
相关文献

参考文献7

1金镇,高琳.宫颈成熟与促宫颈成熟药物[J].实用药物与临床,2005,8(3):1-3. 被引量：16
2Imada K,Ito A, Sato T, et aL Hormonal regulation of matrix metalloproteinase 9/gelatiase B gene expression in rabbit uterine cervical fibroblasts[ J]. Biol Reprod,1997,56 (3 ): 575 -580.
3Nagase H,Woessner JF Jr. Matrix metalloproteinases[ J]. J Biol Chem, 1999,274 (31) : 21491 -21494.
4陈芳,孙晓溪.基质金属蛋白酶在生殖系统中的研究现状[J].生殖与避孕,2008,28(2):103-107. 被引量：6
5Hulboy DL, Rudoloh LA,Matrisian LM. Matrix metalloproteinases as mediators of reproductive function[ J]. Mol Hum Reprod, 1997,3 (1): 27-45.
6Ledingham MA, Denison FC, Riley SC, et al. Matrix metal-loproteinases - 2 and ~ 9 and their inhibitors are produced by the human uterine cervix but their secretion is not regulated by nitric oxide donors[J]. Hum Reprod, 1999, 14 ( 8): 2089 -2096.
7Aronsson A,Ulfgren AK,St^bi B,et al. The effect of orally and vaginally administered misoprostol on inflammatory mediators and cervical ripening during early pregnancy[ J]. Contraception ,2005,72 (1) : 33 - 39.

二级参考文献32

1李志凌,李慰玑.透明质酸酶促子宫颈成熟的研究[J].中华妇产科杂志,1993,28(10):592-594. 被引量：7
2翁梨驹,焦丽娅,唐小奈.米非司酮配伍前列腺素终止早孕的子宫颈组织学变化[J].中华妇产科杂志,1995,30(9):522-525. 被引量：561
3冀春萱,俞志明,叶苓,李莉,潘德,王玮.妇女妊娠期及分娩前后子宫肌层的超微结构研究[J].中华物理医学杂志,1995,17(2):91-93. 被引量：4
4李秀华,栾少红,王霞.妊高征孕妇使用催产素引产产程观察[J].现代妇产科进展,1996,5(2):149-151. 被引量：3
5Vu TH, Werb Z. Matrix metaUoproteinases:effectors of development and normal physiology. Genes Dev, 2000,14 (17):2123-33.
6Plaisier M, Koolwijk P, Hanemaaijer R, et al. Membrane-type matrix metalloproteinases and vascularization in human endometrium during the menstrual cycle. Mol Hum Reprod, 2006,12(1):11-8.
7Thomas E, Curry JR, Kevin GO. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocrinol Soci, 2003, 24(4):428-65.
8Osteen KG, Bruner-Tran KL, Ong DE, et al. Paracrine mediators ofendometrial matrix metalloproteinase expression: potential targets for progestin-based treatment of endometriosis. Ann NY Acad Sci, 2002, 955(3):139-46.
9Sivridis E, Giatromanolaki A. New insights into the normal menstrual cycle-regulatory molecules. Histol Histopthol, 2004, 19(2):511-6.
10Cornet PB,Galant C, Eeckhout Y, et al. Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J Clin Endocrinol Metab, 2005, 90(2):1001-11.